Title
A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
Phase
Phase 2Lead Sponsor
New York Glaucoma Research InstituteStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Chronic Angle-closure GlaucomaIntervention/Treatment
verosudil ...Study Participants
10To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6 months.
Secondary Outcome
Secondary objectives are:
To evaluate the early effect of Rho kinase Inhibitor (AR-12286) in reducing intraocular pressure (IOP).
To evaluate the long term effect of the drug on IOP.
To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.
AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
Inclusion Criteria: Patients between 50 and 85 years old; of either sex. Patients with CACG with ≥180⁰ PAS IOP ≥22 mmHg prior to initiation of treatment in one or both eyes with two measurements taken two hours apart No previous intraocular surgery except clear cornea phacoemulsification. Corrected visual acuity in both eyes ≥20/50 in the eligible eye Not more than 6 diopters spherical equivalent on the study eye Not more than 3 diopters cylinder equivalent on the study eye Have given written informed consent, prior to any investigational procedures. Ability to attend for the 6-month duration of the study Exclusion Criteria: Open angle glaucoma Closed angle glaucoma with <180⁰ PAS Intraocular pressure >35 mmHg Severe glaucomatous damage Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics. Previous intraocular surgery except clear cornea phacoemulsification. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study. Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or drops for treatment of dry eye syndrome (which may be used throughout the study). Any abnormality preventing reliable applanation tonometry of either eye. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study. Changes of systemic medication that could have a substantial effect on IOP anticipated during the study. Participation in any investigational study within the past 30 days. Inability to perform reliable VF testing. Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary. Self-reported poor compliance to treatment. Reluctance to return for scheduled follow-up visits. Patients not able to understand the nature of the study.
